MBX Biosciences Q1 net loss $23.5M; Phase 3 canvuparatide start on track for Q3 2026

MBX Biosciences, Inc.

2026-Q1 EPS reported -$0.50

Cash, equivalents and marketable securities of $440M; expected to fund operations into 2029.
R&D expenses $18.5M (down from $22.4M YoY); G&A expenses $8.8M (up from $4.1M YoY).
Phase 3 trial of once-weekly canvuparatide for hypoparathyroidism to initiate in Q3 2026 after successful FDA End-of-Phase 2 meeting.
Appointed Mark Soued as Chief Commercial Officer; he led Alnylam's US amyloidosis business and AMVUTTRA launch.
Obesity Day on May 11 to present initial blinded MBX 4291 Phase 1 data; amycretin prodrug nomination expected this quarter.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

MBX Biosciences, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026, was $23.5 million.

Period: first quarter ended March 31, 2026
Net income: Net loss for the three months ended March 31, 2026, was $23.5 million
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2026, was $23.5 million compared to a net loss of $23.9 million for the same period in 2025.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

MBX Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-210825

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.